Cyclerion Therapeutics Inc (OQ:CYCN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 301 Binney Street
CAMBRIDGE MA 02142
Tel: N/A
Website: https://www.cyclerion.com
IR: See website
<
Key People
Regina Graul
President
Anjeza Gjino
Chief Financial Officer, Corporate Secretary
Cheryl Gault
Chief Operating Officer
Business Overview
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company's portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Financial Overview
For the fiscal year ended 31 December 2023, Cyclerion Therapeutics Inc revenues decreased from $297K to $0K. Net loss before extraordinary items decreased 31% to $12.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 81% to $646K (expense).
Employees: 1 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1.10M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$9.65M as of Dec 31, 2023
Net annual income (TTM): -$12.59M as of Dec 31, 2023
Free cash flow (TTM): -$21.25M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 2,710,096 as of Feb 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.